These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36844935)

  • 1. Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report.
    Rösch M; Bieg C; Savic S; Buess M
    Case Rep Oncol; 2023; 16(1):109-115. PubMed ID: 36844935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
    Asper N; Roth KS; Hany TF; Salzberg SP; Tinguely M; Kadvany Y; Trojan A
    Case Rep Oncol; 2023; 16(1):1500-1507. PubMed ID: 38033416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic salivary duct carcinoma in cardiac and pleural effusions: A case report with immunocytochemical analysis for androgen receptor and HER2.
    Ito H; Ishida M; Sando K; Okano K; Ebisu Y; Fujisawa T; Iwai H; Tsuta K
    Mol Clin Oncol; 2019 Jan; 10(1):78-82. PubMed ID: 30655980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
    You Y; Wang P; Wan X; Xu L; Gong Y; Zhang W
    Onco Targets Ther; 2021; 14():3481-3486. PubMed ID: 34093024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
    Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
    Front Oncol; 2020; 10():559057. PubMed ID: 33123470
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib.
    Sorenson KR; Piovezani Ramos G; Villasboas Bisneto JC; Price K
    Case Rep Oncol; 2017; 10(2):726-731. PubMed ID: 28878657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
    Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
    Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N; Minami S; Fujii M
    Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
    Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
    J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report.
    Wasano K; Sakurai K; Kawasaki T; Kusafuka K; Kasahara M; Kondo N; Inada KI; Ogawa K
    Rare Tumors; 2018; 10():2036361318798867. PubMed ID: 30263102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD; Moyers J; Thung I; Thinn MM
    Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report.
    Bergamini C; Cavalieri S; Sanguineti G; Farneti A; Licitra L
    Oxf Med Case Reports; 2019 Oct; 2019(10):omz102. PubMed ID: 31772741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up.
    Gokavarapu S; Fonseca D; Puthamakula S; Reddy BP; Reddy BS; Murthy S
    Int J Surg Case Rep; 2015; 8C():22-4. PubMed ID: 25603487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
    Kawakita D; Nagao T; Takahashi H; Kano S; Honma Y; Hirai H; Saigusa N; Akazawa K; Tani K; Ojiri H; Tsukahara K; Ozawa H; Okami K; Kondo T; Togashi T; Fushimi C; Shimura T; Shimizu A; Okamoto I; Okada T; Imanishi Y; Watanabe Y; Otsuka K; Sakai A; Ebisumoto K; Sato Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Ando M; Matsuki T; Nakaguro M; Sato Y; Urano M; Utsumi Y; Kohsaka S; Saotome T; Tada Y
    Ther Adv Med Oncol; 2022; 14():17588359221119538. PubMed ID: 36090801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
    Ueki Y; Tada Y; Togashi T; Kawakita D; Nagao T; Sato Y
    Int Cancer Conf J; 2016 Jul; 5(3):150-153. PubMed ID: 31149444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer.
    Yajima S; Nakanishi Y; Matsumoto S; Tanabe K; Masuda H
    J Maxillofac Oral Surg; 2022 Dec; 21(4):1097-1100. PubMed ID: 36896090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report.
    Čavka L; Zakotnik B
    J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
    Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
    Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma.
    Gogineni E; Sells BE; Dibs K; Jhawar SR; Haring CT; Limbach AL; Konieczkowski DJ; Ma SJ; Zhu S; Baliga S; Mitchell DL; Grecula JC; Bonomi M; Bhateja P; Old MO; Seim NB; Kang SY; Rocco JW; Chakravarti A; Blakaj DM; Gamez ME
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.